Red raspberry found to prevent head and neck cancers from developing and spreading

(Natural News) Berries are known to be one of the greatest superfoods available. Many studies suggest that these are rich in antioxidants and possess cancer-fighting properties. For example, red raspberry — a type of berry scientifically known as Rubus idaeus — can protect against a type of head and neck cancer called nasopharyngeal cancer, according...
Source: - Category: Consumer Health News Source Type: news

Related Links:

Conclusion: rs28362491 polymorphism was significantly associated with the risk of HNCs, especially with NC. Additionally, our results showed that no association was discovered between rs2233406 polymorphism and HNCs. PMID: 31612070 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
For HNC patients, RT is an essential curative and organ-preserving treatment modality, which can be delivered by itself or combined with chemotherapy or surgery. However, several reports have demonstrated that RT is related to an increased risk of CVD in HNC patients [1 –3]. It might have resulted from the chronic side effects of RT on the large to medium vasculatures of the head and neck [1,4,5]. The exact mechanism of radiation-induced carotid or cerebral artery injury is not clear, but the intima-media thickness of the common carotid artery was reported to be significantly increased in nasopharyngeal cancer patien...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
ConclusionPulmonary metastasectomy for lesions originating from head and neck provides good long-term survival. Histological subtype was the only statistically significant prognostic factor.
Source: Indian Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
CONCLUSION: Individual methods showed dosimetric advantages on certain aspects, and the UTCI of the BAO treatment plans are marginally greater in the case of maxillary sinus and parotid gland. However, if treatment time was included into consideration, VMAT plans would be recommended for cancers of the nasopharynx, oral cavity, and larynx. PMID: 31593367 [PubMed - as supplied by publisher]
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
In this study, we overexpressed LMP1 in two NPC cell lines and found elevated level of cytokeratin 19 (CK19) expression. CK19 is an undifferentiated keratin and a stem cell marker. We also have found an increased number of ALDH positive cells along with LMP1 overexpression in both cell lines. Our data demonstrate that LMP1 regulates the maintenance of ALDH-1 positive NPC cancer stem cells, thus shedding light on target therapy of NPC in clinical application. Keywords: nasopharyngeal carcinoma; latent membrane protein 1; aldehyde dehydrogenase; cancer stem cells. PMID: 31507199 [PubMed - in process]
Source: Acta Virologica - Category: Infectious Diseases Authors: Tags: Acta Virol Source Type: research
CONCLUSION: There is no evidence of benefit from the addition of cetuximab to standard management protocols, and there is some evidence of increased toxicity. There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies. PMID: 31506113 [PubMed - as supplied by publisher]
Source: Journal of Laryngology and Otology - Category: ENT & OMF Tags: J Laryngol Otol Source Type: research
Conclusion.Not only was the stroke risk in NPC survivors higher than that in the general population, but the onset age was also 10 years earlier. Future survivorship care should include ischemic stroke as a late complication, for its proper prevention and management.Implications for Practice.Nasopharyngeal carcinoma (NPC) is endemic in Taiwan, and its 5‐year survival is 65.2%. With the increased 5‐year cancer survivors, survivorship has become an important issue. However, research on NPC survivorship is very rare. To the authors’ knowledge, this is the first population‐based study on long‐term NPC survivors. ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Head and Neck Cancers, Health Outcomes and Economics of Cancer Care Source Type: research
The previous review by the International Head and Neck Scientific Group (IHNSG) on recurrent nasopharyngeal carcinoma (NPC) summarized the available data that had emerged over the past decade prior to 2010 to identify the scope of the problem [1]. With the adoption of intensity-modulated radiotherapy (IMRT) +/- stereotactic radiotherapy (SRT) for the primary management of NPC in the contemporary era, a renewed review of strategies is needed for the management of recurrent NPC as most failures are now likely to be related to radioresistance.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research
In this study, we investigated the efficacy and specificity of this inhibitor in NPC cell lines, and tumor-bearing mice were used to examine the therapeutic efficacy and effects of RG7388 treatment. The results showed that RG7388 potently decreased cell proliferation and activated p53-dependent pathway, resulting in cell cycle arrest and apoptosis. RG7388 significantly inhibited tumors in tumor-bearing mice. Activation of the p53 pathway-inhibited cell proliferation, as observed by detecting Ki67-positive cells. Additionally, the activity of apoptotic caspase family proteins was induced in the cleaved caspase-3-positive ce...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
AbstractHead and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of pa...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Head and Neck Cancer | Health | Nasopharyngeal Cancer | Raspberries | Study